P688 Patient preferences in medication to treat Ulcerative Colitis: a discrete choice experiment

Abstract Background Since the number of treatment options for Ulcerative Colitis (UC) has expanded, patients and physicians face challenges regarding decisions about medication options. In shared decision making, treating help understand trade-offs their own preferences. We aimed to identify preferences relative risks benefits UC in with Netherlands. Furthermore, we assessed after how many failed options, are willing consider surgical treatment. Methods conducted a web-based, discrete choice experiment (DCE) among adult patients. Patients were repeatedly asked choose between two hypothetical varying combinations attribute levels (fig 1). Attributes based on consecutively literature search, patient interviews, surveys focus group. The six included attributes were: administration route, location, chance symptom reduction (short long term), chances infection adverse events. A balanced overlap design was used. recruited via association Crohn & NL academic hospitals. Data analyzed by using Hierarchical Bayes estimation. Results total 172 participated DCE. Median disease duration 8 (IQR 3-16) years. Most anti-TNF experienced (52.9%). Symptom one year (relative importance (RI) 27.7 (95% CI 25.6-29.7)) most important when choosing (table 1), followed (22.3 (21.2 - 23.4)) eight weeks (RI 19.5 (18.1 20.9)). location events least (8.7 (7.7 9.79) 8.5 (7.9 9.2), respectively). preferred oral over subcutaneous injections. Intravenous route favorite. differences average utilities previous treated biologic therapy or small molecules naïve displayed table 2. 133 filled trade off questions surgery. Forty-four (33.1%) responded unknown. Nineteen (14.3%) would not even surgery failing all without any new available therapies left. Nine before trying Of remaining patients, nine (6.8%) Conclusion found that These outcomes can